US FDA issues its first ever non-compliance notice for not posting trial results

FDA gave Acceleron Pharma 30 days to file data which should have been posted on clinicaltrials.gov by Nov 2018 from a phase II study of dalantercept and axitinib in advanced renal cancer (which completed in Nov 2017), or face a fine of $10 000 a day and/or criminal penalties.

British Medical Journal